|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:ATCCode
|
L01EX08
|
|
gptkbp:CASNumber
|
170364-57-1
|
|
gptkbp:clinicalTrialPhase
|
Phase III (as of 2023)
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:hasInChIKey
|
QJQYQKZDHGJZKJ-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C27H26N6O
|
|
gptkbp:hasSMILES
|
CN1CCN(CC1)C2CCN(C2)C3=CC=C(C=C3)C(=O)NC4=NC=CC(=C4)C5=CN(C6=CC=CC=C56)C
|
|
gptkbp:hasUNII
|
6Z5B6HVF6O
|
|
gptkbp:intendedUse
|
anticancer agent
|
|
gptkbp:IUPACName
|
4-[(3S)-3-(4-methylpiperazin-1-yl)pyrrolidin-1-yl]-N-[4-(1-methylindol-3-yl)pyridin-2-yl]benzamide
|
|
gptkbp:legalStatus
|
investigational
|
|
gptkbp:mechanismOfAction
|
protein kinase C beta inhibitor
|
|
gptkbp:molecularWeight
|
450.5 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201737
9941576
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
LY317615
|
|
gptkbp:target
|
VEGF pathway
protein kinase C beta
|
|
gptkbp:bfsParent
|
gptkb:BridgeBio_Pharma
gptkb:PKCĪ²
gptkb:PKC_beta
gptkb:PKC_theta
gptkb:staurosporine
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
enzastaurin
|